Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure

British Journal of Clinical Pharmacology

Volumn 65, Issue 4, 2008, Pages 511-522

  Albers, Stefanie ^a   Meibohm, Bernd ^b   Mir, Thomas S ^c   Läer, Stephanie ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Carvedilol; Computer simulation; Paediatrics; Pharmacokinetics

Indexed keywords

CARVEDILOL;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CHILD; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; HUMAN; INFANT; MAJOR CLINICAL STUDY; NONLINEAR SYSTEM; ONTOGENY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIMULATION;

ADOLESCENT; ADRENERGIC ALPHA-ANTAGONISTS; ADULT; BODY WEIGHT; CARBAZOLES; CHILD; CHILD, PRESCHOOL; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GERMANY; HEART FAILURE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MODELS, THEORETICAL; PROPANOLAMINES; TREATMENT OUTCOME;

EID: 40549135032     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.03046.x     Document Type: Article

References (42)

1. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996 334 : 1349 55.
2. Bruns LA, Chrisant MK, Lamour JM, Shaddy RE, Pahl E, Blume ED, Hallowell S, Addonizio LJ, Canter CE. Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. J Pediatr 2001 138 : 505 11.
3. Shaddy RE. Beta-adrenergic receptor blockers as therapy in pediatric chronic heart failure. Minerva Pediatr 2001 53 : 297 304.
4. Rusconi P, Gomez-Marin O, Rossique-Gonzalez M, Redha E, Marin JR, Lon-Young M, Wolff GS. Carvedilol in children with cardiomyopathy: 3-year experience at a single institution. J Heart Lung Transplant 2004 23 : 832 8.
5. Azeka E, Franchini Ramires JA, Valler C, Alcides Bocchi E. Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment. J Am Coll Cardiol 2002 40 : 2034 8.
6. Laer S, Mir TS, Behn F, Eiselt M, Scholz H, Venzke A, Meibohm B, Weil J. Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters. Am Heart J 2002 143 : 916 22.
7. Shaddy RE, Boucek MM, Hsu DT, Boucek RJ, Canter CE, Mahony L, Ross RD, Pahl E, Blume ED, Dodd DA, Rosenthal DN, Burr J, LaSalle B, Holubkov R, Lukas MA, Tani LY. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA 2007 298 : 1171 9.
8. von Mollendorff E, Reiff K, Neugebauer G. Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker. Eur J Clin Pharmacol 1987 33 : 511 3.
9. Neugebauer G, Akpan W, von Mollendorff E, Neubert P, Reiff K. Pharmacokinetics and disposition of carvedilol in humans. J Cardiovasc Pharmacol 1987 10 (Suppl. 11 S85 8.
10. Giessmann T, Modess C, Hecker U, Zschiesche M, Dazert P, Kunert-Keil C, Warzok R, Engel G, Weitschies W, Cascorbi I, Kroemer HK, Siegmund W. CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects. Clin Pharmacol Ther 2004 75 : 213 22.
11. Oldham HG, Clarke SE. In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R (+)- and S (-)-carvedilol. Drug Metab Dispos 1997 25 : 970 7.
12. Bachmakov I, Werner U, Endress B, Auge D, Fromm MF. Characterization of beta-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein. Fundam Clin Pharmacol 2006 20 : 273 82.
13. De Mey C, Brendel E, Enterling D. Carvedilol increases the systemic bioavailability of oral digoxin. Br J Clin Pharmacol 1990 29 : 486 90.
14. Leithe ME, Margorien RD, Hermiller JB, Unverferth DV, Leier CV. Relationship between central hemodynamics and regional blood flow in normal subjects and in patients with congestive heart failure. Circulation 1984 69 : 57 64.
15. Tenero D, Boike S, Boyle D, Ilson B, Fesniak HF, Brozena S, Jorkasky D. Steady-state pharmacokinetics of carvedilol and its enantiomers in patients with congestive heart failure. J Clin Pharmacol 2000 40 : 844 53.
16. Behn F, Laer S, Mir TS, Scholz H. Quantification of carvedilol in small plasma volumes from children using high-performance liquid chromatography. Chromatographia 2001 53 : 641 4.
17. Jurima-Romet M, Foster BC, Casley WL, Rode A, Vloshinsky P, Huang HS, Geertsen S. CYP2D6-related oxidation polymorphism in a Canadian Inuit population. Can J Physiol Pharmacol 1997 75 : 165 72.
18. Boeckmann AJ, Sheiner LB, Beal SL. NONMEM Users Guide. San Francisco, CA : NONMEM Project Group, University of California, 1994.
19. Shi J, Ludden TM, Melikian AP, Gastonguay MR, Hinderling PH. Population pharmacokinetics and pharmacodynamics of sotalol in pediatric patients with supraventricular or ventricular tachyarrhythmia. J Pharmacokinet Pharmacodyn 2001 28 : 555 75.
20. Holford NH. A size standard for pharmacokinetics. Clin Pharmacokinet 1996 30 : 329 32.
21. West GB, Brown JH, Enquist BJ. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science 1999 284 : 1677 9.
22. Efron B. Bootstrap methods: another look at the jackknife. Ann Stat 1979 7 : 1 26.
23. Parke J, Holford NH, Charles BG. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed 1999 59 : 19 29.
24. ICH. Clinical Investigation of Medicinal Products in the Paediatric Population. Guideline. Available at http://www.ich.org/LOB/media/MEDIA487.pdf (last accessed: 20 March 2007).
25. Meibohm B, Laer S, Panetta JC, Barrett JS. Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J 2005 7 : E475 87.
26. Rajagopalan P, Gastonguay MR. Population pharmacokinetics of ciprofloxacin in pediatric patients. J Clin Pharmacol 2003 43 : 698 710.
27. Krishna R, Krishnaswami S, Kittner B, Sankoh AJ, Jensen BK. The utility of mixed-effects covariate analysis in rapid selection of doses in pediatric subjects: a case study with fexofenadine hydrochloride. Biopharm Drug Dispos 2004 25 : 373 87.
28. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology - drug disposition, action, and therapy in infants and children. N Engl J Med 2003 349 : 1157 67.
29. Przepiorka D, Blamble D, Hilsenbeck S, Danielson M, Krance R, Chan KW. Tacrolimus clearance is age-dependent within the pediatric population. Bone Marrow Transplant 2000 26 : 601 5.
30. Goresky GV, Koren G, Sabourin MA, Sale JP, Strunin L. The pharmacokinetics of alfentanil in children. Anesthesiology 1987 67 : 654 9.
31. Murry DJ, Crom WR, Reddick WE, Bhargava R, Evans WE. Liver volume as a determinant of drug clearance in children and adolescents. Drug Metab Dispos 1995 23 : 1110 6.
32. Evans WE, Relling MV, de Graaf S, Rodman JH, Pieper JA, Christensen ML, Crom WR. Hepatic drug clearance in children: studies with indocyanine green as a model substrate. J Pharm Sci 1989 78 : 452 6.
33. Tateishi T, Nakura H, Asoh M, Watanabe M, Tanaka M, Kumai T, Takashima S, Imaoka S, Funae Y, Yabusaki Y, Kamataki T, Kobayashi S. A comparison of hepatic cytochrome P450 protein expression between infancy and postinfancy. Life Sci 1997 61 : 2567 74.
34. Leeder JS, Adcock K, Gaedigk A, Gotschall R, Wilson JT, Kearns GL. Acquisition of CYP2D6 and CYP3A4 activities in the first year of life. Clin Pharmacol Ther 2000 67 : 169, OIII-B-163.
35. Hirt D, Urien S, Jullien V, Firtion G, Rey E, Pons G, Blanche S, Treluyer JM. Age-related effects on nelfinavir and M8 pharmacokinetics: a population study with 182 children. Antimicrob Agents Chemother 2006 50 : 910 6.
36. Mahmood B, Daood MJ, Hart C, Hansen TW, Watchko JF. Ontogeny of P-glycoprotein in mouse intestine, liver, and kidney. J Invest Med 2001 49 : 250 7.
37. Labbe L, Sirois C, Pilote S, Arseneault M, Robitaille NM, Turgeon J, Hamelin BA. Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. Pharmacogenetics 2000 10 : 425 38.
38. Blake MJ, Gaedigk A, Pearce RE, Bomgaars LR, Christensen ML, Stowe C, James LP, Wilson JT, Kearns GL, Leeder JS. Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin Pharmacol Ther 2007 81 : 510 6.
39. FDA. Coreg Label Information. Available at http://www.fda.gov/cder/foi/ label/2007/020297s022lbl.pdf (last accessed: 20 March 2007).
40. Behn F. Pharmakokinetik, Pharmakodynamik und Pharmakogenetik von Carvedilol in Abhängigkeit vom Lebensalter bei pädiatrischen Patienten mit Herzinsuffizienz [Dissertation in German]. Hamburg : University of Hamburg, 2001.
41. Johnson JA, Terra SG. Beta-adrenergic receptor polymorphisms: cardiovascular disease associations and pharmacogenetics. Pharm Res 2002 19 : 1779 87.
42. German label information for Dilatrend. Hoffman-La-Roche AG. July 2004.